Obesity in Polycystic Ovary Syndrome: Insulin Sensitizing Therapy

被引：3
作者：
Kathleen M. Hoeger
机构：
[1] University of Rochester Medical Center,Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology
来源：
Current Obesity Reports | 2012年 / 1卷 / 4期
关键词：
Obesity; Polycystic ovary syndrome; Weight reduction; Cardiovascular risk; Adolescents; Adolescent obesity; Metformin; Thiazolidinediones; Fertility risk; Pregnancy complications; Insulin resistance; Type 2 diabetes; Insulin sensitizing therapy;
D O I：
10.1007/s13679-012-0030-y
中图分类号：
学科分类号：
摘要：
Polycystic Ovary Syndrome (PCOS) is a common reproductive endocrine disorder in women that is highly associated with obesity. Whether obesity is intrinsic to the disorder or is a result of different lifestyle and environmental concerns is unclear, however obesity influences the risks of PCOS with respect to fertility complications, pregnancy complications and cardiovascular risk. Polycystic ovary syndrome is known to be associated with insulin resistance in both lean and obese individuals. Insulin resistance in fact is felt to be a key feature in the reproductive and metabolic dysfunction of PCOS. There are numerous studies reporting the benefits of insulin sensitizing therapy, specifically metformin and thiazolidinediones, on the features of PCOS and emerging evidence on the impact of these agents on the risk and management of obesity. Weight loss and maintenance of weight reduction has been seen in women and adolescents treated with metformin therapy. Most studies indicate a synergy of metformin with lifestyle therapy in the general population but there are limited data in PCOS.
引用
收藏
页码：191 / 198
页数：7
相关论文
共 264 条
[1]  
Stein IF(1935)Amenorrhea associated with bilateral polycystic ovaries Am J Obstet Gynecol 29 181-191
[2]  
Asuncion M(2004)Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome Fertil Steril 81 19-25
[3]  
Calvo RM(2000)A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain J Clin Endocrinol Metab 85 2434-8
[4]  
San Millan JL(2003)Genetic and environmental aspect of polycystic ovary syndrome J Endocrinol Invest 26 1151-9
[5]  
Sancho J(2011)Obesity - United States, 1988–2008 MMWR Surveill Summ 60 73-7
[6]  
Avila S(2005)Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment Fertil Steril 83 1454-60
[7]  
Escobar-Morreale HF(2009)Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society Fertil Steril 92 1966-82
[8]  
Carmina E(1994)Body fat distribution has weight-independent effects on clinical, hormonal, and metabolic features of women with polycystic ovary syndrome Metabolism 43 706-13
[9]  
Freedman DS(2008)Endocrine and metabolic differences among phenotypic expressions of polycystic ovary syndrome according to the 2003 Rotterdam consensus criteria Am J Obstet Gynecol 198 670 e1-7
[10]  
DeUgarte CM(1998)Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome Diabetes 38 1165-74
12345678910